Market Outlook

By 2035, the U.S. Structural Heart Devices Market is expected to reach approximately USD 20.80 billion, growing at a CAGR of 10.86% during the forecast period 2026–2035. The market was valued at approximately USD 7.42 billion in 2025, with historical analysis covering 2021 to 2024. During the historical period, the market expanded from an estimated USD 4.22 billion in 2021 to nearly USD 6.71 billion in 2024, supported by rising TAVR volumes, broader use of mitral transcatheter edge-to-edge repair, early commercialization of tricuspid therapies, and growing hospital investment in dedicated structural heart programs.

The U.S. structural heart devices market is moving from a TAVR-led growth cycle into a broader multi-valve intervention cycle. Aortic valve replacement remains the largest revenue contributor, but mitral, tricuspid, left atrial appendage, and septal closure technologies are becoming increasingly important to future market expansion. The clinical need is large because heart valve disease affects a meaningful share of the U.S. adult population, increases sharply with age, and is often diagnosed late. As the U.S. population aged 65 and above continues to expand, hospitals are seeing higher volumes of patients with aortic stenosis, mitral regurgitation, tricuspid regurgitation, atrial fibrillation-related stroke risk, and complex valve-in-valve requirements.

The market is strongly influenced by clinical workflow economics. Structural heart procedures are usually performed in high-acuity hospital environments, hybrid operating rooms, cath labs, and advanced imaging-enabled procedure suites. This makes purchasing behavior different from lower-cost device markets. Hospitals evaluate device adoption based not only on implant price, but also on procedural efficiency, length of stay, ICU utilization, complication rates, reimbursement predictability, referral capture, and the ability to build a differentiated heart center service line. Vendors that support proctoring, patient screening, CT planning, echo guidance, inventory optimization, and payer documentation are likely to gain stronger account penetration.

Introduction

The U.S. Structural Heart Devices Market is shaped by the convergence of aging demographics, expanding transcatheter indications, hospital capital investment, and rapid device innovation across valve repair, valve replacement, occlusion, and closure technologies. Structural heart disease includes defects and functional abnormalities involving the heart valves, chambers, septum, and related cardiac structures. Unlike rhythm management or coronary interventions, structural heart care often requires multidisciplinary coordination between interventional cardiologists, cardiac surgeons, imaging specialists, anesthesiologists, heart failure teams, cath lab staff, and hospital administrators.

The market has matured significantly since transcatheter aortic valve replacement became a mainstream alternative to surgical aortic valve replacement for many patients with severe aortic stenosis. TAVR has created the commercial and clinical foundation for the broader category. Hospitals that initially built TAVR programs are now expanding into mitral TEER, tricuspid repair and replacement, left atrial appendage closure, valve-in-valve interventions, and complex congenital or acquired closure procedures. This installed procedural infrastructure gives the market a powerful platform for incremental device adoption.

In 2025, market demand is being driven by three practical realities. First, a large proportion of structural heart patients are elderly, medically complex, and at higher risk for open-heart surgery. Second, transcatheter therapies allow hospitals to treat patients who may otherwise be managed medically despite poor long-term outcomes. Third, health systems increasingly view structural heart programs as strategic service lines because they attract referrals, support cardiology-surgery collaboration, and create high-value procedural revenue when outcomes and throughput are well managed.

Key Market Drivers: What’s Fueling the U.S. Structural Heart Devices Market Boom?

Rising older-adult population and valve disease burden are the core demand drivers. Aortic stenosis, mitral regurgitation, and tricuspid regurgitation are strongly age-associated conditions. As the U.S. population aged 65 and older expands, the pool of patients requiring valve assessment and intervention will increase. Aortic stenosis remains one of the most commercially important indications because symptomatic severe disease has poor prognosis without timely valve replacement. Mitral and tricuspid regurgitation are also gaining attention as imaging, referral pathways, and device options improve.

The shift from open surgery to transcatheter treatment continues to expand the addressable market. TAVR established the value proposition of less invasive structural heart therapy by reducing recovery time and broadening treatment access for patients who are poor candidates for open surgery. This same logic is now influencing mitral and tricuspid intervention. Hospitals are prioritizing therapies that can shorten length of stay, reduce surgical trauma, and improve patient acceptance, particularly among older adults with multiple comorbidities.

Regulatory and clinical evidence momentum is accelerating adoption. FDA approvals for tricuspid repair and replacement devices have opened a new commercial chapter in structural heart care. These approvals matter because tricuspid regurgitation has historically been undertreated, often managed with medication despite progressive right-sided heart failure risk. New device availability gives heart teams more actionable treatment options and helps manufacturers build differentiated portfolios beyond the aortic valve.

Hospital service-line economics are creating strong procurement incentives. Structural heart programs can generate downstream imaging, diagnostics, procedure, inpatient, and follow-up revenue. A mature structural heart center typically depends on high-end echocardiography, CT planning, anesthesia support, cath lab capacity, hybrid OR access, clinical coordinators, and registry reporting infrastructure. Device vendors that help hospitals increase referral conversion, screen patients efficiently, and reduce procedural variability are better positioned during purchasing decisions.

Medicare coverage and registry infrastructure support market transparency. The U.S. market benefits from established registry-based evidence collection for transcatheter valve therapies. Participation in national registries improves outcomes tracking and supports payer confidence. This is particularly important because many structural heart patients are Medicare beneficiaries. Reimbursement clarity does not remove all hospital margin pressure, but it gives manufacturers and providers a clearer framework for program expansion.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Structural heart device manufacturers are improving performance across three major dimensions: device deliverability, anatomical fit, and long-term procedural planning. In TAVR, innovation is focused on lower-profile delivery systems, improved sealing skirts, commissural alignment, repositionability, reduced paravalvular leak, lower pacemaker rates, and better lifetime management for younger or lower-risk patients. As TAVR moves deeper into lower-risk populations, valve durability, coronary access, and future valve-in-valve planning are becoming central design and marketing themes.

Mitral and tricuspid innovation is more complex because atrioventricular valve anatomy is highly variable. Manufacturers are developing repair and replacement systems that can address leaflet tethering, annular dilation, coaptation gaps, and challenging imaging environments. TEER remains important, but the market is expanding toward replacement technologies, annuloplasty systems, chordal solutions, and combination strategies. The tricuspid valve is especially challenging due to thin leaflets, large annular dimensions, proximity to conduction tissue, and frequent right-heart enlargement. Early commercial success in this category will depend heavily on patient selection, imaging quality, physician training, and predictable procedural workflow.

Left atrial appendage closure is also evolving as hospitals seek stroke-risk reduction options for patients with non-valvular atrial fibrillation who are not ideal long-term anticoagulation candidates. Device differentiation is increasingly tied to complete closure, reduced device-related thrombus, ease of deployment, recapture capability, and post-procedure antithrombotic management pathways. While LAA closure is sometimes categorized separately from valve devices, it remains a meaningful structural heart growth area because it uses many of the same referral channels, imaging resources, and interventional cardiology capabilities.

Digital planning and imaging integration are becoming competitive differentiators. Structural heart procedures depend on pre-procedure CT, intraprocedural echocardiography, fluoroscopy, and operator experience. Vendors are increasingly bundling implants with planning support, simulation tools, training programs, and procedural education. Over the next decade, AI-enabled CT planning, automated annular measurement, device sizing support, echo guidance, and risk prediction tools are likely to improve workflow consistency and reduce the learning curve for complex valve procedures.

Segmentation Insights

The U.S. Structural Heart Devices Market is segmented on the basis of product type, procedure type, application, end user, and region.

By Product Type

Heart Valve Devices

Heart valve devices represent the dominant product category in the U.S. structural heart devices market. This segment includes transcatheter aortic valves, surgical bioprosthetic valves, mitral and tricuspid repair devices, transcatheter mitral replacement systems, transcatheter tricuspid replacement systems, and valve-in-valve solutions. TAVR devices account for the largest share of heart valve device revenue because procedure volumes are high, device prices are premium, and the therapy is supported by extensive clinical evidence. Growth is expected to remain strong as hospitals continue screening patients with symptomatic aortic stenosis and as device durability data supports broader use.

Mitral and tricuspid valve devices are expected to be among the fastest-growing areas. Mitral TEER has already established a meaningful U.S. installed base, while tricuspid devices are entering a more active commercial adoption phase. The market opportunity is large because many patients with moderate-to-severe or severe regurgitation have historically remained undertreated due to surgical risk or limited therapeutic options. As imaging protocols improve and referral pathways mature, heart valve devices will remain the core revenue engine of the market.

Occluders & Closure Devices

Occluders and closure devices form a high-growth segment supported by left atrial appendage closure, atrial septal defect closure, patent foramen ovale closure, ventricular septal defect closure, and paravalvular leak closure. LAA closure is the most commercially attractive subsegment because atrial fibrillation is highly prevalent in older adults and stroke prevention remains a major clinical and economic priority. These devices offer an alternative for selected patients who face bleeding risks or adherence challenges with long-term anticoagulant therapy.

Septal occluders and closure devices are smaller in total revenue compared with TAVR, but they are clinically important and strategically valuable. They allow companies to participate across congenital and acquired structural heart care pathways. These devices also benefit from relatively established procedural workflows and broad physician familiarity. Growth will be supported by improved imaging, better patient selection, and expansion of heart team programs that manage both valve and non-valve structural defects.

Annuloplasty & Repair Systems

Annuloplasty and repair systems are gaining relevance as structural heart therapy moves beyond replacement. These devices are designed to restore valve competence by improving leaflet coaptation, reducing annular dimensions, or repairing functional regurgitation. In mitral and tricuspid disease, repair-based approaches are attractive because they may preserve native anatomy and offer future treatment flexibility. However, adoption depends heavily on anatomy, operator skill, imaging quality, and evidence supporting durable reduction in regurgitation.

This segment is expected to grow steadily through 2035 as hospitals look for device options that can address patients who are not ideal candidates for TEER or replacement. Manufacturers that can simplify repair procedures and demonstrate consistent outcomes across diverse anatomies will be well positioned. Repair systems will also benefit from increased use of patient-specific planning and intraprocedural imaging improvements.

Delivery Systems and Accessories

Delivery systems and accessories are critical to procedural success, even though they are often less visible than the implants themselves. This category includes catheters, guidewires, introducer sheaths, steerable delivery systems, retrieval systems, embolic protection devices, and procedural accessories used in structural heart interventions. Growth is tied directly to rising procedure volume and increasing complexity of cases.

Hospitals value delivery systems that reduce vascular complications, improve device positioning, shorten procedure time, and support predictable deployment. In TAVR, smaller sheath profiles and better catheter control remain important. In mitral and tricuspid procedures, steerability and imaging alignment are even more critical because access routes and valve anatomy are more complex. Device companies that control both implant and delivery platform design can create stronger procedural loyalty among operators.

By Procedure Type

Transcatheter Aortic Valve Replacement

Transcatheter aortic valve replacement remains the dominant procedure type in the U.S. structural heart devices market. TAVR has become a mainstream treatment for many patients with severe aortic stenosis and continues to benefit from large clinical evidence, physician familiarity, and hospital infrastructure. The procedure has shifted from being reserved mainly for inoperable or high-risk patients to serving broader risk categories, with patient selection guided by heart team evaluation, anatomy, age, surgical risk, and lifetime valve strategy.

The commercial opportunity remains strong because aortic stenosis is common in older adults and diagnosis rates continue to improve. Growth is expected to come from earlier referral, broader screening, treatment of intermediate and lower-risk patients, valve-in-valve procedures, and new indications such as aortic regurgitation where appropriate devices are available. However, the TAVR segment will also face scrutiny around durability, coronary access, pacemaker rates, and lifetime management in younger patients.

Transcatheter Mitral Valve Repair & Replacement

Transcatheter mitral valve repair and replacement represents one of the most strategically important growth areas. Mitral regurgitation is a high-burden condition associated with heart failure, hospitalization, reduced quality of life, and increased mortality risk. TEER has established the clinical and commercial foundation of this segment, particularly for selected patients with degenerative or functional mitral regurgitation who are not ideal surgical candidates.

The replacement opportunity remains less mature but potentially significant. Mitral anatomy is more challenging than aortic anatomy because of annular shape, left ventricular interaction, leaflet pathology, and risk of left ventricular outflow tract obstruction. As new systems gain evidence and regulatory progress, this segment may shift from a repair-dominated market to a more balanced repair-and-replacement market. Hospitals with advanced imaging and experienced structural heart teams will lead adoption.

Transcatheter Tricuspid Valve Repair & Replacement

Transcatheter tricuspid valve repair and replacement is expected to be the fastest-growing procedure segment during the forecast period. Historically, tricuspid regurgitation was often treated late or managed medically because isolated surgical tricuspid intervention carried meaningful risk and limited referral momentum. Recent device approvals have changed the commercial outlook by creating viable minimally invasive options for selected patients.

This segment has strong unmet need, but adoption will be methodical. Tricuspid patients often present with advanced right-heart disease, atrial fibrillation, renal dysfunction, liver congestion, and frailty. These factors make patient selection and timing critical. Manufacturers that provide training, screening algorithms, imaging support, and post-market outcomes evidence are likely to shape the category. By 2035, tricuspid intervention could become one of the most important contributors to structural heart market expansion.

Left Atrial Appendage Closure

Left atrial appendage closure is a high-value procedure segment positioned at the intersection of structural heart intervention, electrophysiology, and stroke prevention. The procedure is designed for selected patients with non-valvular atrial fibrillation who need an alternative to long-term oral anticoagulation. Growth is supported by rising atrial fibrillation prevalence, greater awareness of bleeding risk, and increasing physician comfort with percutaneous closure procedures.

The segment is competitive because device performance, closure completeness, ease of deployment, and clinical evidence all influence adoption. Hospitals also evaluate LAA closure based on referral generation from electrophysiology, cardiology, neurology, and primary care networks. As Medicare Advantage and value-based care models focus on avoiding stroke-related costs, LAA closure could gain more strategic importance within cardiovascular service lines.

Septal Defect Closure

Septal defect closure includes atrial septal defect, patent foramen ovale, ventricular septal defect, and selected paravalvular or post-surgical closure applications. Compared with valve interventions, this segment is smaller but stable and clinically necessary. Demand is supported by congenital heart disease management, adult congenital referrals, stroke workups, and improved imaging detection.

Growth will be moderate, with strongest adoption in hospitals that operate comprehensive structural heart and adult congenital heart programs. Device selection is influenced by defect anatomy, device conformability, deliverability, physician familiarity, and safety profile. This segment also contributes to vendor account depth because it complements larger valve and LAA portfolios.

By Application

Aortic Stenosis

Aortic stenosis is the largest application segment in the U.S. structural heart devices market. It is a degenerative condition that becomes more common with age and can progress silently before symptoms appear. Once severe symptomatic disease develops, timely valve replacement becomes critical. TAVR has transformed the management of aortic stenosis by offering a less invasive option for many patients who previously faced high surgical risk or prolonged recovery.

Revenue growth in this application will be supported by expanded screening, improved referral pathways, increasing use of echocardiography among older adults, and ongoing innovation in valve design. Market expansion will also be influenced by debates around treating younger and lower-risk patients, long-term valve durability, and future coronary access. Despite these considerations, aortic stenosis will remain the market’s anchor indication through 2035.

Mitral Regurgitation

Mitral regurgitation is a major growth application because it affects a broad population of patients with degenerative valve disease, heart failure-related functional regurgitation, and complex comorbidities. TEER has enabled treatment for patients who are not suitable for surgery, while new repair and replacement platforms may expand options over time. The market opportunity is large because many patients remain untreated or are referred late.

The clinical and commercial challenge is heterogeneity. Mitral regurgitation can result from leaflet prolapse, annular dilation, ventricular remodeling, chordal disease, or mixed mechanisms. Device companies need strong evidence, clear patient selection criteria, and procedural support to drive adoption. Hospitals that can integrate heart failure clinics, imaging teams, and structural heart coordinators are likely to generate stronger mitral volumes.

Tricuspid Regurgitation

Tricuspid regurgitation is emerging as one of the most attractive applications in structural heart devices. The disease has historically been underdiagnosed and undertreated, but awareness is increasing as clinicians recognize its association with right-sided heart failure, hospitalization, and poor quality of life. The arrival of transcatheter tricuspid repair and replacement devices is creating a new treatment pathway for patients who previously had few practical options.

This application is expected to grow rapidly from a small base. Early adoption will concentrate in high-volume academic centers and advanced structural heart programs, then expand into broader hospital networks as training and evidence mature. The main barriers will be patient selection, imaging complexity, reimbursement workflow, and the need to intervene before end-stage right-heart dysfunction.

Atrial Fibrillation Stroke Risk Reduction

Atrial fibrillation stroke risk reduction supports demand for left atrial appendage closure devices. The left atrial appendage is a major source of thrombus formation in non-valvular atrial fibrillation, and closure devices provide an interventional alternative for selected patients who cannot remain on long-term anticoagulation. This application is commercially attractive because the eligible patient base is large and the economic burden of stroke is significant.

Growth will depend on physician referral behavior, payer documentation, patient awareness, and evidence comparing closure strategies with drug therapy in different risk groups. Hospitals that align electrophysiology, interventional cardiology, neurology, and anticoagulation clinics can build stronger LAA closure programs. Vendors with robust training and patient identification tools will benefit.

Congenital & Acquired Septal Defects

Congenital and acquired septal defects represent a steady application segment. These conditions include atrial septal defects, patent foramen ovale, ventricular septal defects, and other closure needs. Although the total market size is smaller than valve intervention, procedures can be clinically meaningful and often require specialized imaging and device expertise.

This application will grow gradually as adult congenital heart disease programs expand and as stroke workups identify patients who may benefit from closure. The segment is also relevant for pediatric-to-adult transition care, complex congenital programs, and tertiary referral centers. Device performance is evaluated on safety, conformability, residual shunt reduction, and ease of retrieval or repositioning.

By End User

Hospitals & Structural Heart Centers

Hospitals and dedicated structural heart centers dominate the U.S. market. Most structural heart procedures require advanced imaging, cath lab or hybrid OR infrastructure, anesthesia support, surgical backup, ICU access, and multidisciplinary heart team coordination. These requirements make hospitals the primary purchasing and utilization environment for TAVR, mitral TEER, tricuspid intervention, LAA closure, and complex closure procedures.

High-volume hospitals are also more likely to participate in clinical trials, early device launches, and post-market evidence programs. Their procurement behavior is strategic rather than transactional. They evaluate vendors based on clinical evidence, physician preference, service support, training quality, inventory reliability, reimbursement assistance, and the ability to help grow referral volume. Hospitals with strong brand positioning in cardiovascular care will continue to drive premium device adoption.

Ambulatory Cardiac Care Settings

Ambulatory cardiac care settings represent an emerging but limited end-user category. Most structural heart procedures remain hospital-based due to patient complexity, anesthesia needs, and emergency backup requirements. However, ambulatory environments can play a role in pre-procedure evaluation, imaging coordination, follow-up care, anticoagulation management, and long-term patient monitoring.

Over the forecast period, some lower-acuity structural heart workflows may shift partially outside inpatient settings, particularly pre-procedure diagnostics and post-procedure surveillance. Full procedural migration will be limited by safety and regulatory requirements. Still, vendors and hospitals will increasingly build ambulatory referral and follow-up networks to improve throughput and patient experience.

Specialty Cardiology Clinics

Specialty cardiology clinics are important demand generators even when they do not directly purchase implants. These clinics identify symptomatic patients, order echocardiograms, manage atrial fibrillation and heart failure patients, and refer appropriate candidates to structural heart programs. Their influence is especially important for mitral regurgitation, tricuspid regurgitation, and LAA closure because referral timing can determine whether patients receive intervention before advanced disease progression.

Manufacturers and hospitals are likely to invest more in education programs targeting community cardiologists. Better screening protocols, murmur detection, echo interpretation, and referral pathways can expand the treated population. Clinics connected to integrated delivery networks may become critical nodes in structural heart patient funnels.

Academic & Research Institutes

Academic and research institutes are central to innovation, clinical trials, and early adoption. These institutions evaluate new devices, generate evidence, train future operators, and influence national practice patterns. They are especially important in emerging segments such as transcatheter tricuspid replacement, mitral replacement, robotic structural heart intervention, AI-based planning, and complex valve-in-valve strategies.

Although academic centers represent a smaller portion of total procedure sites, they exert outsized influence on product credibility. Manufacturers often work closely with these centers for first-in-human studies, pivotal trials, physician training, and market development. Successful adoption in leading academic centers can accelerate broader acceptance across community hospitals and regional heart networks.

Regional Insights: Where the Market is Growing Fastest

The U.S. Structural Heart Devices Market shows strong regional variation based on older-adult population density, cardiovascular disease burden, academic medical center concentration, hospital network consolidation, Medicare penetration, and access to advanced cath lab infrastructure. The South is expected to represent the largest regional opportunity because of its large population base, high cardiovascular disease burden, rapid hospital network expansion, and large older-adult populations in states such as Florida, Texas, North Carolina, Georgia, and Tennessee. The Northeast remains a high-value region because of dense academic medical centers and advanced referral systems. The West benefits from innovation ecosystems and high procedural sophistication, while the Midwest shows steady growth supported by mature cardiovascular networks and large integrated health systems.

South

The South is expected to hold the largest share of the U.S. structural heart devices market through 2035. The region combines large population scale, a fast-growing older-adult base, high cardiovascular risk factors, and expanding hospital systems. Florida and Texas are particularly important because of their large Medicare populations, major metropolitan health systems, and strong demand for TAVR, LAA closure, and valve repair procedures. Florida’s structural heart opportunity is closely tied to aging demographics and high procedure capacity in markets such as Miami, Tampa, Orlando, Jacksonville, and Naples. Texas benefits from large tertiary centers in Houston, Dallas, Austin, San Antonio, and Fort Worth, along with growing suburban referral networks.

North Carolina and Georgia are becoming increasingly important structural heart markets due to health system investment, population growth, and strong cardiovascular service-line expansion. Tennessee, South Carolina, Alabama, Louisiana, Arkansas, Mississippi, Kentucky, Oklahoma, Virginia, Maryland, West Virginia, and Delaware contribute to regional growth through hospital modernization and referral expansion. However, the South also faces access disparities, rural coverage gaps, and uneven availability of advanced structural heart programs. This creates opportunity for hub-and-spoke models where major heart centers coordinate diagnosis, imaging, intervention, and follow-up across broader catchment areas.

Northeast

The Northeast is one of the most clinically advanced and commercially attractive regions for structural heart devices. New York, Massachusetts, Pennsylvania, New Jersey, Connecticut, Rhode Island, Maine, Vermont, and New Hampshire have dense concentrations of academic medical centers, high specialist availability, advanced imaging capabilities, and strong participation in clinical research. The region is particularly important for early adoption of complex mitral, tricuspid, and valve-in-valve procedures.

New York and Massachusetts are major demand centers because of their advanced hospital networks, high procedure sophistication, and strong research ecosystems. Pennsylvania and New Jersey provide significant market depth through large cardiovascular programs and dense suburban populations. Connecticut and Rhode Island support smaller but high-value markets where access to tertiary centers is relatively strong. The Northeast’s growth rate may be slightly lower than the South because the market is more mature, but per-procedure value and adoption of next-generation devices are expected to remain high.

Midwest

The Midwest represents a stable and strategically important structural heart devices market. Illinois, Ohio, Michigan, Minnesota, Wisconsin, Indiana, Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota have strong cardiovascular care networks, large integrated health systems, and significant older-adult populations. The region is known for disciplined hospital procurement behavior, strong clinical governance, and careful evaluation of new technology before broad adoption.

Illinois, Ohio, Michigan, and Minnesota are the most important Midwest markets due to high-volume heart centers, academic hospitals, and broad referral networks. Wisconsin and Indiana add meaningful procedural volume through mature community hospital systems. Missouri and Iowa support regional hub centers that draw patients from surrounding rural areas. Growth in the Midwest will be driven by TAVR sustainability, expanded LAA closure, and increasing adoption of mitral and tricuspid interventions in advanced centers. Rural access remains a barrier, but telehealth-enabled screening, regional echo networks, and patient transfer pathways can improve structural heart program reach.

West

The West is expected to be one of the fastest-growing regions due to strong innovation ecosystems, high concentration of device companies, advanced hospital systems, and early adoption of new technologies. California is the single most important state in the region because it combines a large population, leading academic centers, device innovation hubs, and major cardiovascular referral networks. Procedure growth is strong in Los Angeles, San Francisco, San Diego, Sacramento, and Orange County. Washington, Oregon, Colorado, Arizona, Nevada, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii contribute to regional expansion at different levels.

Arizona and Nevada are particularly attractive due to growing older-adult populations and migration trends. Colorado, Washington, and Oregon are important for technology-enabled care models, advanced imaging adoption, and high-quality hospital networks. The West also supports early-stage device development because many structural heart innovators, investors, and medtech talent pools are located in California and surrounding states. Geographic distance and rural access challenges remain relevant in states such as Montana, Wyoming, Idaho, Alaska, and New Mexico, but regional centers of excellence will continue to capture complex referrals.

Key Market Players

The U.S. Structural Heart Devices Competitive Landscape is moderately consolidated at the commercial leadership level but highly active at the innovation and pipeline level. Large companies dominate established categories such as TAVR, mitral TEER, LAA closure, and septal occlusion, while specialized innovators are advancing next-generation mitral, tricuspid, aortic regurgitation, annuloplasty, and closure solutions. Competitive advantage depends on clinical outcomes, regulatory approvals, physician training, delivery-system reliability, reimbursement support, and the ability to build full structural heart portfolios rather than single-product positions.

Some of the key players in the U.S. Structural Heart Devices industry are:

Edwards Lifesciences
Abbott
Medtronic
Boston Scientific
W. L. Gore & Associates
AtriCure
Artivion
JenaValve Technology
Corcym
MicroPort Scientific
Foldax
HighLife Medical
Cardiac Dimensions
4C Medical Technologies
InnovHeart
Pi-Cardia
Ancora Heart
Venus Medtech
Meril Life Sciences
Occlutech
Lepu Medical Technology
Shifamed
Valcare Medical
CroíValve
Others

Recent Developments

Recent developments in the U.S. structural heart devices market show that the category is entering a broader innovation phase beyond aortic valve replacement. In 2024, the U.S. market saw important regulatory progress in tricuspid therapies, including transcatheter tricuspid repair and replacement technologies. These developments are significant because tricuspid regurgitation has long been one of the most undertreated structural heart conditions. The availability of commercial device options is expected to stimulate physician education, referral development, and hospital program expansion.

The TAVR market continues to mature, with device companies focusing on next-generation valves, improved delivery systems, lower complication rates, and long-term treatment planning. Procedural growth remains supported by extensive U.S. registry evidence and continued physician confidence. However, manufacturers are increasingly required to address durability, coronary access, future reintervention, and younger-patient treatment strategy. This is changing how companies position TAVR platforms in hospital value committees and clinical discussions.

Mitral and tricuspid innovation is accelerating. TEER remains the leading commercial repair approach, but replacement systems and alternative repair technologies are gaining investor and clinical attention. Companies are working to reduce procedure complexity, improve anatomical eligibility, and generate real-world outcomes evidence. The next wave of growth will likely come from technologies that simplify patient selection and improve reproducibility across centers beyond the highest-volume academic programs.

Left atrial appendage closure remains a competitive growth area. Device companies are improving implant design, surface healing, closure completeness, and deployment control. Hospitals are developing stronger referral pathways from electrophysiology, general cardiology, neurology, and primary care. As more patients seek alternatives to long-term anticoagulation, this segment is expected to remain a meaningful contributor to the structural heart devices market.

Conclusion

The U.S. Structural Heart Devices Market Size & Share is positioned for strong long-term growth as cardiovascular care shifts toward less invasive, image-guided, transcatheter treatment of complex valve and structural heart disease. The market is no longer defined only by TAVR. While aortic valve replacement remains the largest revenue base, the next decade will be shaped by mitral, tricuspid, LAA closure, septal closure, valve-in-valve, and patient-specific procedural planning.

By 2035, the market is expected to reach approximately USD 20.80 billion, supported by a CAGR of 10.86% from 2026 to 2035. Hospitals will continue investing in structural heart programs because these service lines improve referral capture, create high-value procedural revenue, and support differentiated cardiovascular care. Manufacturers that combine strong clinical evidence, reliable delivery platforms, training support, imaging integration, and reimbursement intelligence will be best positioned to win in this market.

The strongest growth opportunities will be seen in tricuspid intervention, mitral replacement and repair expansion, left atrial appendage closure, and advanced TAVR lifetime management. Regional growth will be led by the South because of population scale and disease burden, while the Northeast and West will remain critical for premium innovation adoption. Overall, the U.S. structural heart devices market is moving into a more sophisticated phase where success depends not only on device engineering, but also on clinical workflow integration, evidence generation, and hospital economics.

TABLE OF CONTENT

1. U.S. Structural Heart Devices Market: Market Introduction & Context
1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Model
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Structural Heart Device Manufacturers
1.6.2. Component and Material Suppliers
1.6.3. Hospitals and Structural Heart Centers
1.6.4. Interventional Cardiologists and Cardiac Surgeons
1.6.5. Imaging Specialists and Cath Lab Teams
1.6.6. Group Purchasing Organizations and Integrated Delivery Networks
1.6.7. Payers, Regulators, and Registry Bodies
What this section provides: Introduces the report’s scope, definitions, methodology, assumptions, and stakeholder ecosystem to help clients understand the coverage, reliability, and analytical boundaries of the study.

2. U.S. Structural Heart Devices Market: Executive Summary
2.1. Key Insights & Market Snapshots
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Revenue Opportunity Snapshot, 2025 & 2035
2.5. High-Growth Segment Summary
2.6. Strategic Takeaways for Manufacturers, Hospitals, Investors, and Distributors
What this section provides: Offers a concise but decision-ready market overview, helping clients quickly understand market size, growth outlook, major demand drivers, and strategic investment areas.

3. U.S. Structural Heart Devices Market: Market Dynamics & Outlook
3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Burden of Aortic Stenosis, Mitral Regurgitation, and Tricuspid Regurgitation
3.1.2. Expansion of Transcatheter Structural Heart Procedures
3.1.3. Growth in Older Adult and Medicare-Eligible Patient Populations
3.1.4. Increasing Hospital Investment in Structural Heart Programs
3.1.5. Improved Imaging, Screening, and Heart Team Referral Pathways
3.2. Restraints and Their Impact Analysis
3.2.1. High Device Cost and Hospital Margin Pressure
3.2.2. Complex Procedure Training Requirements
3.2.3. Limited Access in Rural and Low-Volume Markets
3.2.4. Long-Term Durability and Reintervention Concerns
3.3. Opportunities and Their Impact Analysis
3.3.1. Tricuspid Valve Repair and Replacement Expansion
3.3.2. Mitral Valve Replacement Pipeline Commercialization
3.3.3. Left Atrial Appendage Closure Growth
3.3.4. Valve-in-Valve and Lifetime Valve Management
3.3.5. AI-Enabled CT Planning and Procedure Optimization
3.4. Patent & Innovation Analysis, 2021–2025
3.5. Clinical Trial and Registry Landscape
3.6. Reimbursement and Coverage Outlook
What this section provides: Explains the major growth drivers, barriers, opportunities, and innovation trends shaping the market, enabling clients to assess both upside potential and commercialization risk.

4. U.S. Structural Heart Devices Market: Market Environment & Industry
4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Procedure Pricing and Average Selling Price Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Impact of Digitalization on Structural Heart Procedure Planning
4.6. Application & Innovation Landscape
4.7. U.S. FDA Regulatory Framework Analysis
4.8. Medicare Coverage, Coding, and Reimbursement Framework
4.9. Import/Export Restrictions & Tariff Impact
4.10. Government Initiatives and Public Health Priorities
4.11. Impact of Escalating Geopolitical Tensions on Medtech Supply Chains
4.12. Hospital Capital Procurement and Value Committee Decision-Making
What this section provides: Provides a strategic view of industry conditions, procurement behavior, regulatory forces, reimbursement dynamics, pricing trends, and competitive pressures shaping U.S. structural heart device adoption.

5. U.S. Structural Heart Devices Market – By Product Type
5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Heart Valve Devices
5.1.2.1. Transcatheter Aortic Valves
5.1.2.2. Transcatheter Mitral Valve Devices
5.1.2.3. Transcatheter Tricuspid Valve Devices
5.1.2.4. Surgical and Bioprosthetic Valve Devices
5.1.3. Occluders & Closure Devices
5.1.3.1. Left Atrial Appendage Closure Devices
5.1.3.2. Atrial Septal Defect Closure Devices
5.1.3.3. Patent Foramen Ovale Closure Devices
5.1.3.4. Ventricular Septal Defect Closure Devices
5.1.3.5. Paravalvular Leak Closure Devices
5.1.4. Annuloplasty & Repair Systems
5.1.4.1. Mitral Valve Repair Systems
5.1.4.2. Tricuspid Valve Repair Systems
5.1.4.3. Transcatheter Annuloplasty Systems
5.1.5. Delivery Systems & Catheters
5.1.5.1. Transfemoral Delivery Systems
5.1.5.2. Transseptal Delivery Systems
5.1.5.3. Steerable Catheters and Introducer Systems
5.1.6. Accessories & Implant Support Tools
5.1.6.1. Guidewires, Sheaths, and Accessory Kits
5.1.6.2. Embolic Protection and Retrieval Tools
5.1.6.3. Sizing, Planning, and Implant Support Tools
What this section provides: Presents structural heart device categories by product type, helping clients identify where implant demand, platform innovation, and recurring procedure-related revenue are expected to concentrate.

6. U.S. Structural Heart Devices Market – By Procedure Type
6.1. Overview
6.1.1. Segment Share Analysis, By Procedure Type, 2025 & 2035 (%)
6.1.2. Transcatheter Aortic Valve Replacement
6.1.3. Transcatheter Mitral Valve Repair & Replacement
6.1.4. Transcatheter Tricuspid Valve Repair & Replacement
6.1.5. Left Atrial Appendage Closure
6.1.6. Septal Defect & Paravalvular Leak Closure
What this section provides: Breaks down the market by procedure type, helping clients understand which interventions dominate current revenue and which procedure categories are expected to deliver the strongest future growth.

7. U.S. Structural Heart Devices Market – By Application
7.1. Overview
7.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
7.1.2. Aortic Stenosis
7.1.3. Mitral Regurgitation
7.1.4. Tricuspid Regurgitation
7.1.5. Atrial Fibrillation Stroke Risk Reduction
7.1.6. Congenital & Acquired Septal Defects
What this section provides: Focuses on clinical application areas, enabling clients to prioritize demand pockets based on disease burden, treatment penetration, referral behavior, and long-term procedure expansion.

8. U.S. Structural Heart Devices Market – By End User
8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.1.2. Hospitals & Structural Heart Centers
8.1.3. Ambulatory Cardiac Care Settings
8.1.4. Specialty Cardiology Clinics
8.1.5. Academic & Research Institutes
What this section provides: Describes end-user demand channels, helping clients understand where purchasing decisions, referral generation, clinical trials, and structural heart procedure volumes are concentrated.

9. U.S. Structural Heart Devices Market – By Geography
9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
9.1.2. Regional Procedure Volume Outlook
9.1.3. Regional Reimbursement and Hospital Network Overview
9.1.4. State-Level Structural Heart Program Density Indicators

9.2. West Region
9.2.1. Regional Overview & Trends
9.2.2. West Region Structural Heart Devices Key Manufacturers Active in the Region
9.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.5. West Region Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.2.6. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.8. California
9.2.8.1. Overview
9.2.8.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.8.3. California Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.2.8.4. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.8.5. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.9. Washington
9.2.9.1. Overview
9.2.9.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.9.3. Washington Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.2.9.4. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.9.5. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.10. Colorado
9.2.10.1. Overview
9.2.10.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.10.3. Colorado Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.2.10.4. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.10.5. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.11. Arizona
9.2.11.1. Overview
9.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.11.3. Arizona Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.2.11.4. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.11.5. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.12. Oregon
9.2.12.1. Overview
9.2.12.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.12.3. Oregon Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.2.12.4. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.12.5. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.13. Nevada
9.2.13.1. Overview
9.2.13.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.13.3. Nevada Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.2.13.4. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.13.5. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.14. Utah
9.2.14.1. Overview
9.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.14.3. Utah Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.2.14.4. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.14.5. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.15. New Mexico
9.2.15.1. Overview
9.2.15.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.15.3. New Mexico Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.2.15.4. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.15.5. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.16. Idaho
9.2.16.1. Overview
9.2.16.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.16.3. Idaho Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.2.16.4. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.16.5. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.17. Montana
9.2.17.1. Overview
9.2.17.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.17.3. Montana Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.2.17.4. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.17.5. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.18. Wyoming
9.2.18.1. Overview
9.2.18.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.18.3. Wyoming Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.2.18.4. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.18.5. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.19. Alaska
9.2.19.1. Overview
9.2.19.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.19.3. Alaska Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.2.19.4. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.19.5. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.20. Hawaii
9.2.20.1. Overview
9.2.20.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.2.20.3. Hawaii Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.2.20.4. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.20.5. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3. Northeast Region
9.3.1. Regional Overview & Trends
9.3.2. Northeast Region Structural Heart Devices Key Manufacturers Active in the Region
9.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.5. Northeast Region Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.3.6. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.8. New York
9.3.8.1. Overview
9.3.8.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.8.3. New York Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.3.8.4. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.8.5. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.9. Massachusetts
9.3.9.1. Overview
9.3.9.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.9.3. Massachusetts Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.3.9.4. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.9.5. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.10. New Jersey
9.3.10.1. Overview
9.3.10.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.10.3. New Jersey Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.3.10.4. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.10.5. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.11. Pennsylvania
9.3.11.1. Overview
9.3.11.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.11.3. Pennsylvania Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.3.11.4. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.11.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.12. Connecticut
9.3.12.1. Overview
9.3.12.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.12.3. Connecticut Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.3.12.4. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.12.5. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.13. Maine
9.3.13.1. Overview
9.3.13.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.13.3. Maine Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.3.13.4. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.13.5. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.14. Vermont
9.3.14.1. Overview
9.3.14.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.14.3. Vermont Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.3.14.4. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.14.5. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.15. New Hampshire
9.3.15.1. Overview
9.3.15.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.15.3. New Hampshire Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.3.15.4. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.15.5. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.16. Rhode Island
9.3.16.1. Overview
9.3.16.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.16.3. Rhode Island Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.3.16.4. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.16.5. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.3.17. Delaware
9.3.17.1. Overview
9.3.17.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.3.17.3. Delaware Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.3.17.4. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.17.5. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4. South Region
9.4.1. Regional Overview & Trends
9.4.2. South Region Structural Heart Devices Key Manufacturers Active in the Region
9.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.5. South Region Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.6. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.7. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.8. Texas
9.4.8.1. Overview
9.4.8.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.8.3. Texas Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.8.4. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.8.5. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.9. Florida
9.4.9.1. Overview
9.4.9.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.9.3. Florida Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.9.4. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.9.5. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.10. Georgia
9.4.10.1. Overview
9.4.10.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.10.3. Georgia Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.10.4. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.10.5. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.11. North Carolina
9.4.11.1. Overview
9.4.11.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.11.3. North Carolina Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.11.4. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.11.5. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.12. Tennessee
9.4.12.1. Overview
9.4.12.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.12.3. Tennessee Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.12.4. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.12.5. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.13. South Carolina
9.4.13.1. Overview
9.4.13.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.13.3. South Carolina Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.13.4. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.13.5. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.14. Alabama
9.4.14.1. Overview
9.4.14.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.14.3. Alabama Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.14.4. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.14.5. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.15. Mississippi
9.4.15.1. Overview
9.4.15.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.15.3. Mississippi Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.15.4. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.15.5. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.16. Louisiana
9.4.16.1. Overview
9.4.16.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.16.3. Louisiana Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.16.4. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.16.5. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.17. Arkansas
9.4.17.1. Overview
9.4.17.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.17.3. Arkansas Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.17.4. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.17.5. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.18. Kentucky
9.4.18.1. Overview
9.4.18.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.18.3. Kentucky Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.18.4. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.18.5. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.19. Oklahoma
9.4.19.1. Overview
9.4.19.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.19.3. Oklahoma Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.19.4. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.19.5. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.20. Virginia
9.4.20.1. Overview
9.4.20.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.20.3. Virginia Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.20.4. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.20.5. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.21. Maryland
9.4.21.1. Overview
9.4.21.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.21.3. Maryland Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.21.4. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.21.5. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.4.22. West Virginia
9.4.22.1. Overview
9.4.22.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.4.22.3. West Virginia Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.4.22.4. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.22.5. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5. Midwest Region
9.5.1. Regional Overview & Trends
9.5.2. Midwest Region Structural Heart Devices Key Manufacturers Active in the Region
9.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.5. Midwest Region Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.5.6. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.8. Illinois
9.5.8.1. Overview
9.5.8.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.8.3. Illinois Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.5.8.4. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.8.5. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.9. Ohio
9.5.9.1. Overview
9.5.9.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.9.3. Ohio Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.5.9.4. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.9.5. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.10. Michigan
9.5.10.1. Overview
9.5.10.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.10.3. Michigan Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.5.10.4. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.10.5. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.11. Minnesota
9.5.11.1. Overview
9.5.11.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.11.3. Minnesota Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.5.11.4. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.11.5. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.12. Indiana
9.5.12.1. Overview
9.5.12.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.12.3. Indiana Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.5.12.4. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.12.5. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.13. Wisconsin
9.5.13.1. Overview
9.5.13.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.13.3. Wisconsin Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.5.13.4. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.13.5. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.14. Missouri
9.5.14.1. Overview
9.5.14.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.14.3. Missouri Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.5.14.4. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.14.5. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.15. Iowa
9.5.15.1. Overview
9.5.15.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.15.3. Iowa Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.5.15.4. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.15.5. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.16. Kansas
9.5.16.1. Overview
9.5.16.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.16.3. Kansas Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.5.16.4. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.16.5. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.17. Nebraska
9.5.17.1. Overview
9.5.17.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.17.3. Nebraska Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.5.17.4. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.17.5. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.18. North Dakota
9.5.18.1. Overview
9.5.18.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.18.3. North Dakota Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.5.18.4. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.18.5. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.5.19. South Dakota
9.5.19.1. Overview
9.5.19.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
9.5.19.3. South Dakota Market Size and Forecast, By Procedure Type, 2021–2035 (US$ Billion)
9.5.19.4. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.19.5. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

What this section provides: Delivers detailed regional and state-level analysis, supporting clients in identifying structural heart growth hotspots, procedure-volume clusters, hospital procurement opportunities, and geographic expansion priorities.

10. U.S. Structural Heart Devices Market: Competitive Landscape & Company Profiles
10.1. Market Share Analysis, 2025
10.2. Company Positioning Matrix
10.2.1. Leaders
10.2.2. Challengers
10.2.3. Innovators
10.2.4. Emerging Players
10.3. Company Profiles
10.3.1. Edwards Lifesciences
10.3.2. Abbott
10.3.3. Medtronic
10.3.4. Boston Scientific
10.3.5. W. L. Gore & Associates
10.3.6. AtriCure
10.3.7. Artivion
10.3.8. JenaValve Technology
10.3.9. Corcym
10.3.10. MicroPort Scientific
10.3.11. Foldax
10.3.12. HighLife Medical
10.3.13. Cardiac Dimensions
10.3.14. 4C Medical Technologies
10.3.15. InnovHeart
10.3.16. Pi-Cardia
10.3.17. Ancora Heart
10.3.18. Venus Medtech
10.3.19. Meril Life Sciences
10.3.20. Occlutech
10.3.21. Lepu Medical Technology
10.3.22. Shifamed
10.3.23. Valcare Medical
10.3.24. CroíValve
10.3.25. Others
Note: All company profiles will include details under the standard heads mentioned in section 10.3: Overview, Product Portfolio, Structural Heart Strategy, Financials, Clinical Pipeline, U.S. Commercial Presence, and Recent Developments. Customization of the company profiling section can be provided based on client requirements.
What this section provides: Provides competitive benchmarking, company positioning, product portfolio mapping, and strategic assessment of leading and emerging structural heart device manufacturers.

11. U.S. Structural Heart Devices Market: Future Market Outlook, 2025–2035
11.1. Scenario Analysis
11.1.1. Optimistic Scenario
11.1.2. Realistic Scenario
11.1.3. Pessimistic Scenario
11.2. Disruptive Technologies Impact
11.2.1. AI-Enabled Structural Heart Planning
11.2.2. Next-Generation Transcatheter Valve Platforms
11.2.3. Robotic and Image-Guided Cardiac Intervention
11.2.4. Advanced Biomaterials and Valve Durability Innovation
11.3. Emerging Business Trends
11.4. Business Opportunities for Startups and Existing Players
11.5. Procedure Migration and Hospital Service-Line Evolution
11.6. Long-Term Outlook for TAVR, Mitral, Tricuspid, and LAA Closure Markets
What this section provides: Presents forward-looking market scenarios and technology shifts, preparing clients for emerging growth paths, disruption risk, and strategic planning through 2035.

12. U.S. Structural Heart Devices Market: Strategic Recommendations
12.1. Recommendations for Device Manufacturers
12.2. Recommendations for Hospitals and Structural Heart Centers
12.3. Recommendations for Investors and Private Equity Firms
12.4. Recommendations for Distributors and Channel Partners
12.5. Recommendations for New Entrants and Emerging Innovators
12.6. Recommendations for Payers and Value-Based Care Stakeholders
What this section provides: Offers actionable strategy guidance for stakeholders seeking growth, market entry, portfolio expansion, procurement optimization, or competitive advantage in the U.S. structural heart devices market.

13. U.S. Structural Heart Devices Market: Research Appendix
13.1. Abbreviations
13.2. Data Sources
13.3. Market Sizing Methodology
13.4. Forecasting Methodology
13.5. Assumptions and Limitations
13.6. Company Selection Criteria
13.7. Regional Classification Methodology
What this section provides: Gives methodological transparency and supporting definitions, helping clients understand how the market estimates, forecasts, company selections, and regional splits were developed.

14. U.S. Structural Heart Devices Market: Disclaimer
What this section provides: States the report’s disclaimers, legal boundaries, usage limitations, and client responsibilities associated with the report.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: Research Methodology and Forecasting Assumptions
TABLE 3: Primary Interview Respondent Mix and Stakeholder Coverage
TABLE 4: U.S. Structural Heart Devices Market: Executive Summary Snapshot, 2025
TABLE 5: U.S. Structural Heart Devices Market: Historical Market Size, 2021–2024 (USD Billion)
TABLE 6: U.S. Structural Heart Devices Market: Forecast Market Size, 2026–2035 (USD Billion)
TABLE 7: Market Drivers; Impact Analysis
TABLE 8: Market Restraints; Impact Analysis
TABLE 9: Market Opportunities; Impact Analysis
TABLE 10: Patent & Innovation Analysis, 2021–2025
TABLE 11: Clinical Trial and Registry Landscape Snapshot
TABLE 12: PESTEL Analysis Summary
TABLE 13: Porter’s Five Forces Analysis Summary
TABLE 14: Procedure Pricing and Average Selling Price Trend Analysis by Region, 2025–2035
TABLE 15: Value Chain and Supply Chain Analysis
TABLE 16: U.S. FDA Regulatory and Medicare Reimbursement Framework
TABLE 17: Structural Heart Device Procurement Criteria by Hospital Value Committees
TABLE 18: U.S. Structural Heart Devices Market: Product Type Snapshot (2025)
TABLE 19: Segment Dashboard; Definition and Scope, by Product Type
TABLE 20: U.S. Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 21: Heart Valve Devices Market, by Subsegment, 2021–2035 (USD Billion)
TABLE 22: Occluders & Closure Devices Market, by Subsegment, 2021–2035 (USD Billion)
TABLE 23: Annuloplasty & Repair Systems Market, by Subsegment, 2021–2035 (USD Billion)
TABLE 24: Delivery Systems & Catheters Market, by Subsegment, 2021–2035 (USD Billion)
TABLE 25: Accessories & Implant Support Tools Market, by Subsegment, 2021–2035 (USD Billion)
TABLE 26: U.S. Structural Heart Devices Market: Procedure Type Snapshot (2025)
TABLE 27: Segment Dashboard; Definition and Scope, by Procedure Type
TABLE 28: U.S. Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 29: U.S. Structural Heart Devices Market: Application Snapshot (2025)
TABLE 30: Segment Dashboard; Definition and Scope, by Application
TABLE 31: U.S. Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 32: U.S. Structural Heart Devices Market: End User Snapshot (2025)
TABLE 33: Segment Dashboard; Definition and Scope, by End User
TABLE 34: U.S. Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 35: U.S. Structural Heart Devices Market: Regional Snapshot (2025)
TABLE 36: Segment Dashboard; Definition and Scope, by Region
TABLE 37: U.S. Structural Heart Devices Market, by Region, 2021–2035 (USD Billion)
TABLE 38: West Region Structural Heart Devices Market, by State, 2021–2035 (USD Billion)
TABLE 39: West Region Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 40: West Region Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 41: West Region Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 42: West Region Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 43: California Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 44: California Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 45: California Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 46: California Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 47: Washington Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 48: Washington Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 49: Washington Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 50: Washington Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 51: Colorado Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 52: Colorado Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 53: Colorado Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 54: Colorado Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 55: Arizona Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 56: Arizona Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 57: Arizona Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 58: Arizona Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 59: Oregon Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 60: Oregon Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 61: Oregon Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 62: Oregon Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 63: Nevada Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 64: Nevada Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 65: Nevada Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 66: Nevada Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 67: Utah Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 68: Utah Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 69: Utah Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 70: Utah Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 71: New Mexico Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 72: New Mexico Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 73: New Mexico Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 74: New Mexico Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 75: Idaho Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 76: Idaho Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 77: Idaho Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 78: Idaho Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 79: Montana Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 80: Montana Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 81: Montana Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 82: Montana Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 83: Wyoming Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 84: Wyoming Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 85: Wyoming Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 86: Wyoming Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 87: Alaska Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 88: Alaska Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 89: Alaska Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 90: Alaska Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 91: Hawaii Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 92: Hawaii Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 93: Hawaii Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 94: Hawaii Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 95: Northeast Region Structural Heart Devices Market, by State, 2021–2035 (USD Billion)
TABLE 96: Northeast Region Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 97: Northeast Region Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 98: Northeast Region Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 99: Northeast Region Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 100: New York Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 101: New York Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 102: New York Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 103: New York Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 104: Massachusetts Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 105: Massachusetts Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 106: Massachusetts Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 107: Massachusetts Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 108: New Jersey Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 109: New Jersey Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 110: New Jersey Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 111: New Jersey Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 112: Pennsylvania Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 113: Pennsylvania Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 114: Pennsylvania Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 115: Pennsylvania Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 116: Connecticut Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 117: Connecticut Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 118: Connecticut Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 119: Connecticut Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 120: Maine Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 121: Maine Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 122: Maine Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 123: Maine Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 124: Vermont Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 125: Vermont Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 126: Vermont Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 127: Vermont Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 128: New Hampshire Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 129: New Hampshire Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 130: New Hampshire Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 131: New Hampshire Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 132: Rhode Island Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 133: Rhode Island Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 134: Rhode Island Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 135: Rhode Island Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 136: Delaware Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 137: Delaware Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 138: Delaware Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 139: Delaware Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 140: South Region Structural Heart Devices Market, by State, 2021–2035 (USD Billion)
TABLE 141: South Region Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 142: South Region Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 143: South Region Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 144: South Region Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 145: Texas Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 146: Texas Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 147: Texas Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 148: Texas Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 149: Florida Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 150: Florida Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 151: Florida Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 152: Florida Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 153: Georgia Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 154: Georgia Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 155: Georgia Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 156: Georgia Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 157: North Carolina Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 158: North Carolina Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 159: North Carolina Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 160: North Carolina Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 161: Tennessee Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 162: Tennessee Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 163: Tennessee Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 164: Tennessee Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 165: South Carolina Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 166: South Carolina Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 167: South Carolina Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 168: South Carolina Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 169: Alabama Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 170: Alabama Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 171: Alabama Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 172: Alabama Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 173: Mississippi Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 174: Mississippi Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 175: Mississippi Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 176: Mississippi Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 177: Louisiana Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 178: Louisiana Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 179: Louisiana Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 180: Louisiana Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 181: Arkansas Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 182: Arkansas Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 183: Arkansas Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 184: Arkansas Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 185: Kentucky Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 186: Kentucky Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 187: Kentucky Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 188: Kentucky Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 189: Oklahoma Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 190: Oklahoma Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 191: Oklahoma Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 192: Oklahoma Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 193: Virginia Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 194: Virginia Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 195: Virginia Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 196: Virginia Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 197: Maryland Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 198: Maryland Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 199: Maryland Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 200: Maryland Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 201: West Virginia Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 202: West Virginia Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 203: West Virginia Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 204: West Virginia Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 205: Midwest Region Structural Heart Devices Market, by State, 2021–2035 (USD Billion)
TABLE 206: Midwest Region Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 207: Midwest Region Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 208: Midwest Region Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 209: Midwest Region Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 210: Illinois Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 211: Illinois Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 212: Illinois Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 213: Illinois Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 214: Ohio Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 215: Ohio Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 216: Ohio Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 217: Ohio Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 218: Michigan Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 219: Michigan Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 220: Michigan Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 221: Michigan Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 222: Minnesota Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 223: Minnesota Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 224: Minnesota Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 225: Minnesota Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 226: Indiana Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 227: Indiana Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 228: Indiana Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 229: Indiana Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 230: Wisconsin Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 231: Wisconsin Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 232: Wisconsin Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 233: Wisconsin Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 234: Missouri Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 235: Missouri Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 236: Missouri Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 237: Missouri Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 238: Iowa Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 239: Iowa Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 240: Iowa Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 241: Iowa Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 242: Kansas Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 243: Kansas Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 244: Kansas Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 245: Kansas Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 246: Nebraska Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 247: Nebraska Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 248: Nebraska Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 249: Nebraska Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 250: North Dakota Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 251: North Dakota Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 252: North Dakota Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 253: North Dakota Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 254: South Dakota Structural Heart Devices Market, by Product Type, 2021–2035 (USD Billion)
TABLE 255: South Dakota Structural Heart Devices Market, by Procedure Type, 2021–2035 (USD Billion)
TABLE 256: South Dakota Structural Heart Devices Market, by Application, 2021–2035 (USD Billion)
TABLE 257: South Dakota Structural Heart Devices Market, by End User, 2021–2035 (USD Billion)
TABLE 258: U.S. Structural Heart Devices Market: Competitive Landscape Snapshot (2025)
TABLE 259: U.S. Structural Heart Devices Market: Key Company Market Share Analysis (2025)
TABLE 260: Company Positioning Matrix; Leaders, Challengers, Innovators and Emerging Players
TABLE 261: Key Players’ Structural Heart Product Portfolio Mapping
TABLE 262: Recent Developments and Regulatory Approval Mapping
TABLE 263: Future Market Outlook Scenario Analysis, 2025–2035
TABLE 264: Disruptive Technology Impact Assessment
TABLE 265: Emerging Business Trends and Investment Opportunity Mapping
TABLE 266: Strategic Recommendations Matrix by Stakeholder Group
TABLE 267: Report Disclaimer and Data Limitation Summary

List of Figures

FIGURE 1: U.S. Structural Heart Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Historical and Forecast Market Size Trend, 2021–2035 (USD Billion)
FIGURE 4: Market Attractiveness Analysis
FIGURE 5: Value Chain Analysis
FIGURE 6: PESTEL Analysis
FIGURE 7: Porter’s Five Forces Analysis
FIGURE 8: Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: U.S. FDA Regulatory and Medicare Reimbursement Framework
FIGURE 11: Procedure Pricing and Average Selling Price Trend Analysis by Region, 2025–2035
FIGURE 12: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 13: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 14: Heart Valve Devices Subsegment Market Share Analysis, 2025 & 2035
FIGURE 15: Occluders & Closure Devices Subsegment Market Share Analysis, 2025 & 2035
FIGURE 16: Procedure Type Segment Market Share Analysis, 2025 & 2035
FIGURE 17: Procedure Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 18: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 19: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 20: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 21: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 22: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 23: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 24: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 25: Company Positioning Matrix, 2025
FIGURE 26: Future Market Outlook Scenario Analysis, 2025–2035
FIGURE 27: West Region Structural Heart Devices Market Share and Leading Players, 2025
FIGURE 28: West Region Market Share Analysis by State, 2025
FIGURE 29: West Region Market Size Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 30: West Region Segment Opportunity Heatmap, 2025–2035
FIGURE 31: California Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 32: Washington Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 33: Colorado Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 34: Arizona Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 35: Oregon Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 36: Nevada Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 37: Utah Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 38: New Mexico Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 39: Idaho Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 40: Montana Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 41: Wyoming Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 42: Alaska Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 43: Hawaii Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 44: Northeast Region Structural Heart Devices Market Share and Leading Players, 2025
FIGURE 45: Northeast Region Market Share Analysis by State, 2025
FIGURE 46: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 47: Northeast Region Segment Opportunity Heatmap, 2025–2035
FIGURE 48: New York Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 49: Massachusetts Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 50: New Jersey Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 51: Pennsylvania Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 52: Connecticut Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 53: Maine Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 54: Vermont Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 55: New Hampshire Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 56: Rhode Island Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 57: Delaware Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 58: South Region Structural Heart Devices Market Share and Leading Players, 2025
FIGURE 59: South Region Market Share Analysis by State, 2025
FIGURE 60: South Region Market Size Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 61: South Region Segment Opportunity Heatmap, 2025–2035
FIGURE 62: Texas Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 63: Florida Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 64: Georgia Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 65: North Carolina Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 66: Tennessee Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 67: South Carolina Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 68: Alabama Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 69: Mississippi Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 70: Louisiana Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 71: Arkansas Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 72: Kentucky Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 73: Oklahoma Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 74: Virginia Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 75: Maryland Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 76: West Virginia Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 77: Midwest Region Structural Heart Devices Market Share and Leading Players, 2025
FIGURE 78: Midwest Region Market Share Analysis by State, 2025
FIGURE 79: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 80: Midwest Region Segment Opportunity Heatmap, 2025–2035
FIGURE 81: Illinois Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 82: Ohio Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 83: Michigan Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 84: Minnesota Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 85: Indiana Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 86: Wisconsin Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 87: Missouri Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 88: Iowa Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 89: Kansas Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 90: Nebraska Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 91: North Dakota Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 92: South Dakota Structural Heart Devices Market Size, Forecast and Trend Analysis, 2021–2035 (USD Billion)
FIGURE 93: TAVR Procedure Opportunity Heatmap by Region, 2025–2035
FIGURE 94: Mitral Valve Repair & Replacement Opportunity Heatmap by Region, 2025–2035
FIGURE 95: Tricuspid Valve Repair & Replacement Opportunity Heatmap by Region, 2025–2035
FIGURE 96: Left Atrial Appendage Closure Opportunity Heatmap by Region, 2025–2035
FIGURE 97: Strategic Recommendations Framework by Stakeholder Group